NCT03393026已完成4 期
A Multi-Center, Open-Label, Single Arm and Flexible Dose Study of the Effectiveness and Safety of Oral Use Lurasidone HCl Tablet (LATUDA®) for 40-160 mg/Day in Subjects With Schizophrenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 2
- 主要终点
- time to treatment failure.
研究概览
简要总结
The study evaluates the effectiveness and safety of Lurasidone in subjects with schizophrenia over a period of 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or female aged at 20-75 years old
- •Subjects who are diagnosed with schizophrenia based on Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria
- •CGI-S≦4 (at both screening and baseline)
- •Subject is judged by the investigator to have been clinically stable for at least 4 weeks prior to baseline and in need for a switch from their current antipsychotic treatment due to insufficient clinical response or poor tolerability (side effects, metabolic complications, etc.).
- •If the subject recruits from OPD, the subject should be intolerant to the AE or is insufficient in current antipsychotics treatment by investigator's judgment.
- •Childbearing potential women who consented to the consistent use of the acceptable contraception (oral contraceptive, contraceptive injection, intrauterine device, double barrier method and contraceptive patch)
- •Subject is able and agrees to remain off (or stable dosage) prior antipsychotic medication during the study period as defined by this protocol.
- •In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the investigator and to participate in, and to comply with, the requirements of the entire protocol.
- •Subject is willing and able to comply with the protocol.
排除标准
- •Subject has clinically substantial risk of suicide or violent behavior as judged by the investigator.
- •Subject with the past history of neuroleptic malignant syndrome, water intoxication, paralytic ileus or dementia related psychosis
- •Subjects is active pregnancy (must have a negative pregnancy test at screening) or nursing (must not be lactating).
- •Subject has received treatment with MAO inhibitors within 14 days prior to the screening (Visit 1).
- •Subject is currently participating, or has participated in, a study with an investigational or marketed compound or device within 1 month prior to signing the informed consent.
- •Subject is unstable or critical untreated medical illness by the judgment of investigators.
- •Subject who is otherwise considered ineligible for the study by investigator. For example, subjects experienced serious medical condition including known clinically relevant laboratory abnormalities, and hypersensitivity to Lurasidone.
- •Subjects who were considered resistance to treatment for psychotic symptoms by the investigator.
- •Total daily dose of pre-switch antipsychotic was exceeded the equivalent of haloperidol 12 mg/day.
- •Subjects have received long depot neuroleptics within 4 weeks prior to enrollment. Or, subject was treated with clozapine for refractory psychosis within 1 month of enrollment.
- •Subject requires treatment with any potent CYP3A4 inhibitors or inducers during the study. Subject requires treatment with a drug that consistently prolongs the QTc interval.
研究组 & 干预措施
Lurasidone 40-160 mg
Experimental
Lurasidone 40-160 mg
干预措施: Lurasidone (Drug)
结局指标
主要结局
time to treatment failure.
时间窗: 6 weeks
Treatment failure is defined as any occurrence of: Insufficient clinical response Exacerbation of underlying disease Discontinuation due to adverse event
次要结局
- Clinical Global Impression-Severity (CGI-S)(6 weeks)
- Clinical Global Impression-Improvement (CGI-I) Scale(6 weeks)
- Positive and Negative Syndrome Scale(PANSS) total scores(6 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable SchizophreniaSchizophreniaSchizoaffective DisorderNCT00641745Sumitomo Pharma America, Inc.629
已完成
3 期
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic SchizophreniaChronic SchizophreniaNCT00789698Sumitomo Pharma America, Inc.240
已完成
3 期
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.SchizophreniaNCT00790192Sumitomo Pharma America, Inc.488
已完成
3 期
Lurasidone HCl A Phase 3 Study of Patients With Acute SchizophreniaSchizophreniaNCT00615433Sumitomo Pharma America, Inc.478
已完成
3 期
Lurasidone HCl: A Phase 3 Study of Patients With Acute SchizophreniaSchizophreniaNCT00549718Sumitomo Pharma America, Inc.489